Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(®) to Suppress Enzalutamide-resistant Prostate Cancer Progression

BACKGROUND: While androgen-deprivation-therapy with the recently developed anti-androgen enzalutamide (Enz) shows promising therapeutic benefits in men with metastatic castration-resistant prostate cancer (PCa), many patients develop resistance to Enz, which may involve the induction of the androgen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur Urol
Autores principales: Wang, Ronghao, Sun, Yin, Li, Lei, Niu, Yuanjie, Lin, Wanying, Lin, Changyi, Antonarakis, Emmanuel S., Luo, Jun, Yeh, Shuyuan, Chang, Chawnshang
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5802348/
https://ncbi.nlm.nih.gov/pubmed/28528814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2017.04.005
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares